Novel therapeutic approaches for recurrent nonmuscle invasive bladder cancer

Urologic Clinics of North America

Volumn 42, Issue 2, 2015, Pages 159-168

  Boehm, Brock E ^a   Svatek, Robert S ^a  

^a University of Texas Health Science Center   (United States)

Author keywords

Bladder; Cancer; Novel; Therapeutics

Indexed keywords

ABI 009; ALT 801; ALT 803; ANTINEOPLASTIC AGENT; APAZIQUONE; BC 819; BCG VACCINE; CD40 LIGAND; CG 0070; FALIMAREV; HYBRID PROTEIN; INSTILADRIN; LENALIDOMIDE; MELANOMA ANTIGEN 3; MITOMYCIN; ONCOLYTIC ADENOVIRUS; OPORTUZUMAB MONATOX; PACLITAXEL; PEMBROLIZUMAB; PIRARUBICIN; RECOMBINANT HYALURONIDASE; TAMOXIFEN; TMX 101; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; VESIGENURTUCEL L; CANCER VACCINE; CYTOTOXIN; IMMUNOLOGICAL ADJUVANT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOHYPERTHERMIA; DISEASE FREE SURVIVAL; DRUG DELIVERY SYSTEM; ELECTROMOTIVE DRUG ADMINISTRATION; GENERAL MEDICAL DEVICE; HUMAN; HYDROGEL; HYPERTHERMIA; HYPERTHERMIC THERAPY; NON MUSCLE INVASIVE BLADDER CANCER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; THERMOCHEMOTHERAPY; TREATMENT RESPONSE; GENE THERAPY; INTRAVESICAL DRUG ADMINISTRATION; MOLECULARLY TARGETED THERAPY; PATHOLOGY; TUMOR INVASION; TUMOR RECURRENCE; URINARY BLADDER NEOPLASMS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; BCG VACCINE; CANCER VACCINES; CYTOTOXINS; DRUG DELIVERY SYSTEMS; GENETIC THERAPY; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; URINARY BLADDER NEOPLASMS;

EID: 84955379021     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2015.02.001     Document Type: Review

References (47)

1. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Zlotta AR, Fleshner NE, Jewett MA. The management of BCG failure in non-muscle-invasive bladder cancer: an update. Can Urol Assoc J 2009;3:S199-205.
3. GuhaSarkar S, Banerjee R. Intravesical drug delivery: challenges, current status, opportunities and novel strategies. J Control Release 2010;148:147-59.
4. Wientjes MG, Badalament RA, Wang RC, et al. Penetration of mitomycin C in human bladder. Cancer Res 1993;53:3314-20.
5. Di Stasi SM, Vespasiani G, Giannantoni A, et al. Electromotive delivery of mitomycin C into human bladder wall. Cancer Res 1997;57:875-80.
6. Di Stasi SM, Giannantoni A, Giurioli A, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 2006;7:43-51.
7. Di Stasi SM, Valenti M, Verri C, et al. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. Lancet Oncol 2011;12:871-9.
8. Sparreboom A, Scripture CD, Trieu V, et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 2005;11:4136-43.
9. McKiernan JM, Barlow LJ, Laudano MA, et al. A phase I trial of intravesical nanoparticle albuminbound paclitaxel in the treatment of bacillus Calmette-Guerin refractory nonmuscle invasive bladder cancer. J Urol 2011;186:448-51.
10. McKiernan JM, Holder DD, Ghandour RA, et al. Phase II trial of intravesical nanoparticle albuminboundpaclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-Guerin treatment failure. J Urol 2014;192:1633-8.
11. Jagannath C, Lindsey DR, Dhandayuthapani S, et al. Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells. Nat Med 2009;15:267-76.
12. Seager CM, Puzio-Kuter AM, Patel T, et al. Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer. Cancer Prev Res (Phila) 2009;2:1008-14.
13. Niranjan R, Koushik C, Saravanan S, et al. A novel injectable temperature-sensitive zinc doped chitosan/beta-glycerophosphate hydrogel for bone tissue engineering. Int J Biol Macromol 2013;54:24-9.
14. Delto JC, Kobayashi T, Benson M, et al. Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progression. Oncotarget 2013;4:269-76.
15. Arends TJ, van der Heijden AG, Witjes JA. Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer. J Urol 2014;192:708-13.
16. Colombo R, Salonia A, Leib Z, et al. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int 2011;107:912-8.
17. Kiss B, Schneider S, Thalmann GN, et al. Is thermochemotherapy with the Synergo system a viable treatment option in patients with recurrent nonmuscle-invasive bladder cancer? Int J Urol 2014; 22(2):158-62.
18. Inman BA, Stauffer PR, Craciunescu OA, et al. A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscleinvasive bladder cancer. Int J Hyperthermia 2014; 30:171-5.
19. NIH. vol. 2015. Available at: ClinicalTrials.gov. 2014. Accessed January 3, 2015.
20. Loskog A, Dzojic H, Vikman S, et al. Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor Microenvironment. J Immunol 2004;172:7200-5.
21. Malmstrom PU, Loskog AS, Lindqvist CA, et al. AdCD40L immunogene therapy for bladder carcinoma-the first phase I/IIa trial. Clin Cancer Res 2010;16:3279-87.
22. Miyamoto H, Shuin T, Torigoe S, Iwasaki Y, Kubota Y. Retinoblastoma gene mutations in primary human bladder cancer. British J Cancer 1995;71:831-5.
23. Ramesh N, Ge Y, Ennist DL, et al. CG0070, a conditionally replicating granulocyte macrophage colonystimulating factor-armed oncolytic adenovirus for the treatment of bladder cancer. Clin Cancer Res 2006;12:305-13.
24. Burke JM, Lamm DL, Meng MV, et al. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol 2012; 188:2391-7.
25. Nagabhushan TL, Maneval DC, Benedict WF, et al. Enhancement of intravesical delivery with Syn3 potentiates interferon-alpha2b gene therapy for superficial bladder cancer. Cytokine Growth Factor Rev 2007;18:389-94.
26. Tao Z, Connor RJ, Ashoori F, et al. Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation. Cancer Gene Ther 2006;13:125-30.
27. Benedict WF, Tao Z, Kim CS, et al. Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. Mol Ther 2004;10:525-32.
28. Connor RJ, Anderson JM, Machemer T, et al. Sustained intravesical interferon protein exposure is achieved using an adenoviral-mediated gene delivery system: a study in rats evaluating dosing regimens. Urology 2005;66:224-9.
29. Dinney CP, Fisher MB, Navai N, et al. Phase I trial of intravesical recombinant adenovirus mediated interferon-alpha2b formulated in Syn3 for Bacillus Calmette-Guerin failures in nonmuscle invasive bladder cancer. J Urol 2013;190:850-6.
30. Sidi AA, Ohana P, Benjamin S, et al. Phase I/II marker lesion study of intravesical BC-819 DNA plasmid in H19 over expressing superficial bladder cancer refractory to bacillus Calmette-Guerin. J Urol 2008;180:2379-83.
31. Gofrit ON, Benjamin S, Halachmi S, et al. DNA based therapy with diphtheria toxin-A BC-819: a phase 2b marker lesion trial in patients with intermediate risk nonmuscle invasive bladder cancer. J Urol 2014;191:1697-702.
32. Morales A, Chin JL, Ramsey EW. Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder. J Urol 2001;166:1633-7 [discussion: 1637-8].
33. Luo Y, Henning J, O'Donnell MA. Th1 cytokinesecreting recombinant Mycobacterium bovis bacillus Calmette-Guerin and prospective use in immunotherapy of bladder cancer. Clin Dev Immunol 2011; 2011:728930.
34. Gerard C, Baudson N, Ory T, et al. Tumor mouse model confirms MAGE-A3 cancer immunotherapeutic as an efficient inducer of long-lasting antitumoral responses. PLoS One 2014;9:e94883.
35. Hendricksen K, van der Heijden AG, Cornel EB, et al. Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer. World J Urol 2009;27:337-42.
36. Hendricksen K, Cornel EB, de Reijke TM, et al. Phase 2 study of adjuvant intravesical instillations of apaziquone for high risk nonmuscle invasive bladder cancer. J Urol 2012;187:1195-9.
37. Li Q, Xu T, Wang XF. Mechanism of intravesical instillation of pirarubicin for preventing recurrence of non-muscle invasive bladder cancer. Zhonghua zhong liu za zhi 2009;31:904-7 [in Chinese].
38. Okamura K, Ono Y, Kinukawa T, et al. Randomized study of single early instillation of (2"R)-4'-O-tetrahydropyranyl-doxorubicin for a single superficial bladder carcinoma. Cancer 2002;94:2363-8.
39. Li NC, Ye ZQ, Na YQ, CUA THP Immediate Instillations Study Group. Efficacy of immediate instillation combined with regular instillations of pirarubicin for Ta and T1 transitional cell bladder cancer after transurethral resection: a prospective, randomized, multicenter study. Chin Med J 2013;126:2805-9.
40. Kowalski M, Guindon J, Brazas L, et al. A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guerin. J Urol 2012;188:1712-8.
41. McGrath M, Michaud DS, De Vivo I. Hormonal and reproductive factors and the risk of bladder cancer in women. Am J Epidemiol 2006;163:236-44.
42. Abstracts of papers presented at the thirtieth annual meeting of the American Society for Cell Biology. San Diego, California. December 9-13, 1990. The Journal of Cell Biology 111, 1a-511a (1990).
43. George SK, Tovar-Sepulveda V, Shen SS, et al. Chemoprevention of BBN-induced bladder carcinogenesis by the selective estrogen receptor modulator tamoxifen. Transl Oncol 2013;6:244-55.
44. Jinesh GG, Lee EK, Tran J, et al. Lenalidomide augments the efficacy of bacillus Calmette-Guerin (BCG) immunotherapy in vivo. Urol Oncol 2013;31: 1676-82.
45. Smith EB, Schwartz M, Kawamoto H, et al. Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder. J Urol 2007;177:2347-51.
46. Hayashi T, Crain B, Corr M, et al. Intravesical toll-like receptor 7 agonist R-837: optimization of its formulation in an orthotopic mouse model of bladder cancer. Int J Urol 2010;17:483-90.
47. Falke J, Lammers RJ, Arentsen HC, et al. Results of a phase 1 dose escalation study of intravesical TMX-101 in patients with nonmuscle invasive bladder cancer. J Urol 2013;189:2077-82.